Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
SkinBioTherapeutics secures £1.56m from new investors
(Sharecast News) - SkinBioTherapeutics announced on Friday that it has secured an investment of £1.56m on Friday, removing any uncertainty around its medium-term financing. The AIM-traded firm said it raised the funds through placing 14,875,749 shares at 10.5p each, with new investors Premier Miton and Cynosure Capital.
It said it was not actively seeking additional funding, as it was already funded until the first quarter of 2025.
However, the investment removed any uncertainty about medium-term financing, would support the delivery of its current project pipeline, and strengthen its balance sheet, potentially facilitating future acquisitions.
The additional £1.44m net of expenses raised would be used to further the roll-out of AxisBiotix-Ps, support the commercialisation of its acne treatment, and potentially cover the deferred consideration for Dermatonics in 2025.
It would also provide general working capital and reduce the need for additional borrowing under any acquisition financing facilities.
The investment completed the share authorisation granted at the company's last annual general meeting in December, with the board saying it did not intend to seek further authorisation before the next AGM.
It said the placing shares were expected to be admitted to trading on AIM on 7 August and would rank equally with existing shares, including the right to receive dividends.
The issue price represented a 26.3% discount to the closing price on 1 August.
"It's extremely rare for small cap companies to be proactively approached by larger investors in this manner, and the support of Premier Miton and Cynosure Capital is a real endorsement of the huge potential of our business," said chief executive officer Stuart Ashman.
"This funding now extends our cash runway through 2025, removing any uncertainty in the short-to-medium term and underpinning our ability to deliver the exciting projects that we currently have underway.
"Whilst further dilution was not something we undertook lightly, we are not seeking any further authority to issue shares this year."
At 1435 BST, shares in SkinBioTherapeutics were down 1.77% at 14p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
